In a groundbreaking study poised to redefine our understanding of the biological underpinnings of aging, researchers at The University of Texas MD Anderson Cancer Center have identified a novel molecular mechanism that links nucleic acid structures known as R-loops to the chronic inflammation typically seen in aged tissues—a phenomenon commonly termed “inflammaging.” Published recently in the prestigious journal Nature Aging, this research not only elucidates a hitherto unknown driver of age-related inflammatory processes but also charts a promising therapeutic path using an existing FDA-approved drug to mitigate this chronic condition.
Inflammaging is increasingly recognized as a central culprit behind a host of degenerative diseases such as cancer, cardiovascular disorders, and metabolic syndromes. Despite extensive study, the cellular and molecular triggers of this persistent low-grade inflammation remained elusive. Rugang Zhang, Ph.D., professor and chair of Experimental Therapeutics at MD Anderson, led the investigative team that discovered how aging cells increasingly export R-loops—exotic nucleic acid structures—from their nuclei into the cytoplasm, setting off an inflammatory cascade.
At its core, an R-loop is a three-stranded nucleic acid formation that arises transiently during transcription when an RNA-DNA hybrid displaces a single strand of DNA. Under normal physiological conditions, R-loops are tightly regulated and confined within the nucleus. However, Zhang’s team demonstrated that senescent cells, characterized by their permanent exit from the cell cycle, display a marked increase in exporting these R-loops to the cytoplasm. Once outside the nucleus, these R-loops bind to DNA fragments floating in the cytoplasm, mistakenly signaling an immune alarm.
This aberrant immune activation resembles a malfunctioning smoke detector that continuously blares despite the absence of fire. The immune system, triggered by these mistaken nucleic acid signals, initiates a widespread inflammatory response that persists chronically, resulting in tissue damage and functional decline often observed in aged organisms. This discovery fills a critical gap in understanding how senescent cells contribute to inflammaging at the molecular level.
Delving deeper, the study identified the two key proteins that form the molecular machinery enabling this R-loop export: DDX1 and XPO1. DDX1 acts as a shuttle by binding R-loops within the nucleus, while XPO1 functions as a gatekeeper, facilitating the translocation of this complex across the nuclear membrane. This nuclear export system, the researchers found, is a pivotal control point driving the inflammation-inducing presence of R-loops in the cytoplasm.
Intriguingly, the research team exploited existing pharmacological interventions by repurposing selinexor (KPT-330), an FDA-approved drug currently used to treat multiple myeloma. Selinexor specifically inhibits the nuclear export protein XPO1, effectively trapping R-loops within the nucleus and preventing their cytoplasmic mislocalization. Preclinical models treated with selinexor showed profound reductions in systemic inflammation, liver fibrosis, aberrant fat accumulation, and muscle wasting—hallmarks of aging pathology.
Moreover, the blockade of R-loop nuclear export not only abated inflammation but also led to a striking increase in lifespan in animal models. This finding suggests that modulating nucleic acid trafficking represents an actionable target for delaying age-associated functional decline and potentially extending healthspan. The therapeutic implications of this discovery are vast, offering a clinically translatable strategy using a drug with an established safety profile.
However, the researchers caution that the inflammatory alarm triggered by R-loop and DNA fragment interactions may also play beneficial roles, such as aiding immune surveillance against precancerous cells. Therefore, completely silencing this alarm might impair protective immune functions. Future therapeutic endeavors might benefit from selectively targeting DDX1, disrupting the R-loop shuttle without broadly shutting down nuclear export, thereby minimizing potential side effects.
This study also opens new avenues for investigating why cells escalate R-loop export as they age. Unraveling the upstream regulatory mechanisms may illuminate further insights into senescence biology and how cellular aging contributes to systemic pathologies. Detailed exploration of how DNA damage responses and nuclear architecture influence R-loop dynamics will be critical to developing refined and targeted interventions.
The convergence of molecular biology and translational medicine underscored in this research exemplifies how deep mechanistic understanding can seed innovative therapies for complex age-related conditions. The use of selinexor as a proof-of-concept therapeutic strategy heralds an era wherein aging, once deemed immutable, is approached as a modifiable risk factor through molecular precision medicine.
As the global population ages, the burden of chronic inflammatory diseases continues to rise, underscoring the urgent need for effective anti-inflammaging interventions. These findings invigorate hope for tangible clinical solutions that can improve quality of life in the elderly and reduce the health care costs associated with aging populations worldwide.
The next critical steps involve rigorous clinical evaluation of nuclear export inhibitors in aging populations while monitoring for immune competence. Furthermore, delineating the fine line between beneficial versus deleterious inflammatory signaling will refine therapeutic windows and guide patient-specific treatments.
In summary, Rugang Zhang and colleagues’ elucidation of R-loop export mechanisms driving inflammaging represents a transformative advance in aging research. Their identification of selinexor’s potential to suppress this process paves the way for repurposed drug interventions that could ameliorate the devastating effects of age-related chronic inflammation and related morbidities.
Subject of Research: Molecular mechanisms of age-related inflammation and therapeutic targeting of R-loop nuclear export
Article Title: Study identifies a new cause of age-related inflammation, suggesting promising treatment pathway
News Publication Date: 16-Jun-2026
Web References:
https://www.mdanderson.org/
https://www.nature.com/articles/s43587-026-01147-6
Image Credits: The University of Texas MD Anderson Cancer Center
Keywords: inflammaging, R-loops, aging, chronic inflammation, senescence, nuclear export, selinexor, KPT-330, DDX1, XPO1, molecular therapeutics, lifespan extension
Tags: age-associated degenerative diseasesage-related inflammationchronic inflammation in aged tissuesFDA-approved drugs for inflammaginginflammaging molecular mechanismsMD Anderson aging researchmolecular triggers of inflammagingnovel therapies for chronic inflammationnucleic acid structures in inflammationR-loop induced inflammatory cascadeR-loops in agingtranscription-related inflammation mechanisms
